EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
about
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domainDiagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert GroupThe Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic TestingNew modalities of cancer treatment for NSCLC: focus on immunotherapyNavigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnosticsThe role of the immune system in non-small cell lung carcinoma and potential for therapeutic interventionTesting for ROS1 in non-small cell lung cancer: a review with recommendationsALK-rearrangements and testing methods in non-small cell lung cancer: a reviewAccurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryChromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Chromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and TreatmentConcomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizoConcordance of IHC, FISH and RT-PCR for EML4-ALK rearrangementsMolecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondComprehensive Molecular Analysis of NSCLC; Clinicopathological AssociationsTotal Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerALK alteration is a frequent event in aggressive breast cancers.EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer.Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersOcular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.In situ Protein Detection for Companion Diagnostics.ALK gene amplification is associated with poor prognosis in colorectal carcinomaThe molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation.The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients.Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.Prognostic and predictive biomarkers in lung cancer. A review.Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
P2860
Q24294276-6FB87DD2-9B93-464A-AFCE-E8F4CE01080EQ26780457-F1479AB3-0433-4A4E-B9BC-1E0CCA38055EQ26824315-59F370E2-FD24-4AA5-A844-5A431B802E8FQ26829161-4720123F-369A-4BCD-A7C9-3F341C6B4B80Q26864332-15D689FD-F113-47D7-8EE3-A243006EDF9FQ27024781-7A63BDCD-46FD-4BE4-B227-7B1827CD35BFQ28070062-F6FC778A-18CD-4305-90A7-78481780068DQ33776835-41F76606-3669-4EA6-8901-BE7A1036A440Q34231928-F6272023-CB62-4F62-BEFE-7F6BA5B9F4D8Q34349164-1F909D7D-C162-4428-AB22-C7E595022CAEQ34388696-71937D59-B5F6-44A1-81E7-C0E9485F59D0Q34389047-5326DFB3-71A2-4766-B8F2-F1F772A3E98EQ34489837-9884D297-4D6B-45B3-9E51-AA0A300DDE82Q34558586-BC9AD191-E60B-40B9-8A74-77DF40C55B15Q34662576-257C7F5C-45D4-47C3-8C4B-FBEDD461D532Q35054450-363D7B98-BFD6-463F-875D-9AF021DD5F5DQ35200526-7373B9C3-0365-4C48-A594-AF55C7464922Q35256622-A7C40486-F88C-4201-AD6D-8E2385E4C196Q35712214-2364E6EF-9238-44CE-89DB-8CD1FA7A2F6BQ36006242-BB704E35-D3CB-44A9-87CF-B414993BB9FEQ36096398-96E8CFB8-ACA5-46A0-B355-F33B66ECC226Q36105958-BA0F4456-ABD4-48AF-9B8B-D6FBE65F3A2AQ36335816-FACACF25-660B-4AFF-8F3F-5B5FC9C0F642Q36741251-127C38AC-A436-47DE-AD6C-F3F4529C2F4BQ36962487-BA993333-44EF-4170-95FB-29BD5505BBDBQ37163460-FFAF904F-8371-4920-8E67-B2D0DA291F47Q37270405-9BB45EB7-29F0-48A1-B7B4-F6A81CCBF756Q37323062-87F946C9-A6F0-440E-A19C-7FC57F39A653Q37431563-E62CA272-E407-48C4-8911-BA7D6FC5BF1EQ37454444-1BB6F57A-40AA-403A-9281-4BC40957DF93Q37496847-4628F1C2-5F01-40FC-B0E4-1F360E90D362Q37601901-CC89D9B5-B804-4560-8C94-B85A5BC5303FQ37631021-3FC3F7E8-CB6E-4875-9630-AA51589782EFQ37644815-E530032B-C944-44F2-B9A9-54B5E303FA61Q37645226-A4DD9B2D-D84D-4E1B-9012-0510391FFFD9Q38087648-CCAC3470-08BC-4E7F-B7EA-14C2B6158FCCQ38101614-249F2910-982A-4421-81C0-EAB5D6FAA2A6Q38178187-286855F0-C386-431D-8969-DDE7B2667A7EQ38202398-2CA61B67-F608-41CC-9471-128A7564417FQ38203468-90FC82A0-A6A5-4BC1-9D6F-9DAE003E7B8F
P2860
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@ast
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@en
type
label
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@ast
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@en
prefLabel
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@ast
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@en
P2093
P2860
P50
P921
P1433
P1476
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
@en
P2093
Fernando Lopez-Rios
Giulio Rossi
Göran Elmberger
Holger Moch
Keith Kerr
Lukas Bubendorf
Patrick Pauwels
Wlodzimierz Olszewski
P2860
P2888
P304
P356
10.1007/S00428-012-1281-4
P577
2012-07-24T00:00:00Z
2012-09-01T00:00:00Z